A screen for inhibitory peptides of hepatitis C virus identifies a novel entry inhibitor targeting E1 and E2

Peiqi Yin1,2, Ling Zhang2, Fei Ye2, Yao Deng2, Sha Lu3, Yi-Ping Li4, Leiliang Zhang1 & Wenjie Tan2

Hepatitis C virus (HCV) entry into hepatocytes is a multistep process that represents a promising target for antiviral intervention. The viral envelope protein E1E2 plays a critical role in HCV entry. In this study, we sought to identify peptide inhibitors of HCV by screening a library of overlapping peptides covering E1E2. Screening the peptide library identified several novel anti-HCV peptides. Four peptides from glycoprotein E2 were selected for further investigation. The 50% effective dose (ED50) was approximately 5 nM for each peptide. Our data indicated that these peptides inhibited HCV entry at the post-attachment step. Moreover, these peptides blocked cell-to-cell transmission of HCVcc and had broad-spectrum antiviral effects on HCVcc. These peptides exhibited combination inhibitory effects on HCVcc infection when combined with IFN-α2b or anti-CD81 antibody. Interestingly, we observed that E2-42 associated with E1 and E2. Our results indicate that E2-42 inhibits HCV entry via E1 and E2. These findings suggest a new avenue for HCV therapeutic development.

Chronic hepatitis C virus (HCV) infection is a major cause of chronic liver diseases, including chronic hepatitis, liver cirrhosis and hepatocellular carcinoma (HCC). Recent estimates suggest that 64–103 million people are infected with HCV worldwide1. No effective vaccine against HCV infection is available, and treatment with PEGylated interferon alpha (PEGIFN-α) plus ribavirin is associated with a response rate of only approximately 40% in patients infected with the most prevalent genotype, genotype 1. Although recently developed direct-acting antivirals (DAAs), including inhibitors of HCV NS3/4 A protease (Boceprevir, Telaprevir, and Simeprevir), NS5A (Daclatasvir, Ledipasvir, and Ombitasvir), and NS5B polymerase (Sofosbuvir, Mericitabine, and Dasabuvir), have revolutionized hepatitis C treatment, several important challenges remain2,3. Potential adverse effects, the risks of selecting drug-resistant mutants, drug-drug interactions, and difficult-to-treat populations are important issues that limit the availability of DAAs to all HCV-infected patients4. More importantly, the high cost of DAAs restricts their accessibility in most parts of the world. Thus, continuous development of alternative potential inhibitors that target different steps of the HCV life cycle, including viral entry, is urgently needed.

As a member of the Flaviviridae family, HCV is an enveloped positive-sense single-strand RNA virus. The viral genome encodes structural (core, E1, E2 and p7) and non-structural (NS2, NS3, NS4A, NS4B, NS5A and NS5B) proteins5. Of these, E1 and E2 are important for HCV entry. HCV entry is a multi-step process that begins with the attachment of a viral particle to the cell surface via attachment factors, followed by a complex process involving a series of cellular entry co-receptors, including scavenger receptor class B type 1 (SR-BI)6, CD817, claudin-18, occludin9, and the receptor tyrosine kinases epidermal growth factor receptor (EGFR)10, ephrin receptor A29, Niemann-Pick C1-like 1 (NPC1L1)10, and transferrin receptor 1 (TIR1)10,11,12. The viral particle enters the host cell via clathrin-mediated endocytosis, which is followed by viral genome release, translation, replication, assembly, and exit of progeny virions to complete the HCV life cycle13.

Due to its multi-step nature, HCV entry is an attractive target for inhibiting HCV. Monoclonal antibodies and small molecules inhibiting HCV entry have been considered13,14. Short peptides derived from viral envelope
sequences that contain membrane-transiting motifs have been designed to inhibit virus entry into cells. For example, a peptide derived from the amino acids 710 to 725 of the HCV E2, inhibits HCV pseudoparticle infection15. The amphipathic α-helical peptide C5A derived from the membrane anchor domain of the HCV NS5A protein exhibits significant inhibitory effects against HCV infection in vitro16. Because the strategy of developing antiviral peptides based on viral membrane proteins is feasible, systematic screening of anti-HCV peptides from HCV E1E2 is promising.

In this study, we screened a peptide library from JFH1 E1E2 and identified four novel HCV inhibitory peptides functioning at the post-attachment and viral spread steps. We further determined that one peptide, named E2-42, interacted with E1 and E2. Overall, our work opens a new avenue for screening anti-HCV peptides and uncovers potential anti-HCV agents.

Results
Identification of antiviral peptides from HCV E1E2. To screen peptides that inhibit HCV infection, a peptide library of 126 overlapping peptides (15-mers offset by 10 amino acids for E1, by 11 amino acids for E2) covering the envelope protein E1E2 of the HCV JFH1 strain (GenBank no. AB047639) was designed. The peptides were incubated with the amino acids 710 to 725 of the HCV E2, inhibits HCV pseudoparticle infection15. The amphipathic α-helical peptide C5A derived from the membrane anchor domain of the HCV NS5A protein exhibits significant inhibitory effects against HCV infection in vitro16. Because the strategy of developing antiviral peptides based on viral membrane proteins is feasible, systematic screening of anti-HCV peptides from HCV E1E2 is promising.

In this study, we screened a peptide library from JFH1 E1E2 and identified four novel HCV inhibitory peptides functioning at the post-attachment and viral spread steps. We further determined that one peptide, named E2-42, interacted with E1 and E2. Overall, our work opens a new avenue for screening anti-HCV peptides and uncovers potential anti-HCV agents.

Results
Identification of antiviral peptides from HCV E1E2. To screen peptides that inhibit HCV infection, a peptide library of 126 overlapping peptides (15-mers offset by 10 amino acids for E1, by 11 amino acids for E2) covering the envelope protein E1E2 of the HCV JFH1 strain (GenBank no. AB047639) was designed. The peptides were incubated with the amino acids 710 to 725 of the HCV E2, inhibits HCV pseudoparticle infection15. The amphipathic α-helical peptide C5A derived from the membrane anchor domain of the HCV NS5A protein exhibits significant inhibitory effects against HCV infection in vitro16. Because the strategy of developing antiviral peptides based on viral membrane proteins is feasible, systematic screening of anti-HCV peptides from HCV E1E2 is promising.

In this study, we screened a peptide library from JFH1 E1E2 and identified four novel HCV inhibitory peptides functioning at the post-attachment and viral spread steps. We further determined that one peptide, named E2-42, interacted with E1 and E2. Overall, our work opens a new avenue for screening anti-HCV peptides and uncovers potential anti-HCV agents.

Figure 1. Identification of HCV E1E2-derived peptides with antiviral activity against HCV infection. (A) Effects of E1E2-derived peptides on HCV E1E2-mediated infection. HCVcc Jc1P7NS2Gluc2a was used to screen for antiviral activity. HCVcc was incubated with 10 nM peptides for 1 h prior to addition to Huh7.5/CD81 cells, and Gaussia luciferase activity was assayed 72 h later. The results were normalized to DMSO-treated cells. (B) Characterization of the specificity of inhibitory peptides against HCVcc infection. HCVcc and VSV-Gpp (VSV-G-pseudotyped lentivirus) were incubated with 10 nM peptides for 1 h. Then, Huh7.5/CD81 cells were inoculated for 4 h with virus/peptide mixtures, and Gaussia luciferase activity was assayed 72 h later. IFN-α and anti-CD81 antibodies were used as positive controls, and DMSO was used as a negative control. (C) The ED50 values of peptides were calculated based on their inhibition of HCVcc activity at different peptide concentrations. (D) Cytotoxicity of peptides against Huh7.5/CD81 cells by MTT assay. Each bar represents the average of triplicate data points, with the standard deviation indicated by the error bars.
E2-42, E2-43, E2-78 and E2-79 have broad-spectrum inhibitory effects on different HCV genotypes. To determine the antiviral activity of E2-42, E2-43, E2-78, and E2-79 against different HCV genotypes and subtypes, the four peptides (10 nM) were incubated with different genotypes of HCVcc, including genotype 2a, Jc1p7NS2Gluc2a and J6CGluc2a; genotype 1a/2a, H77/JFHGluc2a; and genotype 1b/2a, HB/JFHGluc2a (Fig. 2A). The virus/peptide mixtures were then used to infect Huh7.5-CD81 cells. The four peptides from E2 exerted broad-spectrum antiviral effects against HCV but different inhibitory efficiencies for different genotypes of HCVcc. Peptides E2-42 and E2-43 had slightly higher efficiency than peptides E2-78 and E2-79. For genotypes 2a, 1a, and 1b, the inhibition rates were 80%, 75% to 80%, and 60% to 70%, respectively (Fig. 2B,C,D and E). The genotype-dependent inhibitory effects may due to differences in amino acid composition among genotypes (Fig. 3A). Next, we synthesized conservative genotype 1a and 1b peptides and evaluated the inhibition ratio for the corresponding genotypes of HCVcc. As shown in Fig. 3B and C, the inhibitory effect of E2-79 from 1a or 1b was significantly decreased compared to that from genotype 2a, indicating that the differences in amino acid composition between genotypes in E2-79 may play an important role in its antiviral effect.

The four peptides inhibit HCV entry and cell-to-cell transmission. To evaluate the effects of peptides on HCV replication, we used an HCV replicon cell line called JFH1 Luc-NS3-5B. After treatment with peptides for 72 h, the replicon cells were lysed to measure luciferase activity. As shown in Fig. 4A, the peptides did not inhibit HCV RNA replication. To analyze whether the peptides had any effect on HCV entry, the peptides were incubated with Huh7.5-CD81 cells at different time points of Jc1p7NS2Gluc infection. The results clearly indicated a decrease in HCVcc infection when the peptides were present during and after virus infection based on luciferase activity measurements (Fig. 4B) and HCV RNA levels (Fig. 4C). Furthermore, there was no effect if peptides were added to the cells as a pretreatment. These results suggest that the four peptides inhibit HCV entry at the post-attachment step.

HCV is also spread via cell-to-cell transmission. After infection with HCVcc, progeny viruses are transmitted from donor cells to acceptor cells, resulting in focal areas of infection transmission. To determine if E2-42, E2-43, E2-78, or E2-79 inhibit cell-to-cell transmission of HCV, Huh7.5-CD81 cells were incubated with HCVcc and overlaid with media containing 50 nM peptides and 1% agarose. After 72 h of infection, the cells were stained with HCV core antibody. Focus sizes were measured by counting the number of cells per focus. As shown in Fig. 4D, E2-78 and E2-79 laid with media containing 50 nM peptides and 1% agarose. After 72 h of infection, the cells were stained with HCV core antibody. Focus sizes were measured by counting the number of cells per focus. As shown in Fig. 4D, E2-78 and E2-79 inhibited cell-to-cell transmission of HCV, Huh7.5-CD81 cells were infected with HCVcc and overlaid with media containing 50 nM peptides and 1% agarose. After 72 h of infection, the cells were stained with HCV core antibody. Focus sizes were measured by counting the number of cells per focus. As shown in Fig. 4D, E2-78 and E2-79 inhibited cell-to-cell transmission of HCV, Huh7.5-CD81 cells were infected with HCVcc and overlaid with media containing 50 nM peptides and 1% agarose. After 72 h of infection, the cells were stained with HCV core antibody. Focus sizes were measured by counting the number of cells per focus. As shown in Fig. 4D, E2-78 and E2-79 inhibited cell-to-cell transmission of HCV, Huh7.5-CD81 cells were infected with HCVcc and overlaid with media containing 50 nM peptides and 1% agarose. After 72 h of infection, the cells were stained with HCV core antibody. Focus sizes were measured by counting the number of cells per focus. As shown in Fig. 4D, E2-78 and E2-79 inhibited cell-to-cell transmission of HCV.

Combination of inhibitory peptides with IFN-α2b or CD81 antibody. To determine if the inhibitory peptides from E2 complement other anti-HCV drugs, we investigated their antiviral activity in combination with IFN-α2b or CD81 antibody. First, we established that the IC50 of IFN-α2b was 100 IU/mL and that the IC50 of CD81 antibody was 1 μg/mL (Fig. 5A). Then, peptides at 2.5 nM or 5 nM in combination with IFN-α2b or CD81 antibody were incubated with genotype 2a HCVcc (Jc1p7NS2Gluc2a) for 2 h and added to Huh7.5-CD81 cells. After 4 h of infection, the virus mixture was removed, and luciferase was measured 72 h later. The results illustrated that the four peptides exhibited combination effects with antiviral IFN-α2b and CD81 antibodies for the inhibition of HCVcc (Fig. 5B). Similar results were observed for genotype 1a HCVcc (H77/JFHGluc2a) and genotype 1b HCVcc (HB/JFHGluc2a) (Fig. 5C and D). Taken together, these results indicate that the four peptides from E2 have potential for combination therapy with IFN-α2b and CD81 antibody.

E2-42 binds HCV envelope proteins but does not interact with HCV receptors. On the surface of HCV particles, E1 forms a trimer in an E2-dependent manner, and both E1 and E2 are required for HCV entry18. Because E2-42, E2-43, E2-78 and E2-79 blocked HCV entry when the peptides were present during and after virus infection, we investigated whether these peptides interact with HCV envelope proteins using a GST pull-down assay. As shown in Fig. 6A and B, E1 and E2 associated with GST-E42 and E42-GST. Compared with E2-42 (residue 548–562), E2-43 (residue 552–566) is lack of sequence from 548 to 551, which is predicted to exposed to the surface and therefore a potential interaction site for E1 and E2 (Fig. 6C). However, the four

| Peptides | Sequence (15 aa) | Position (aa-aa) | AVPid | Sequence |
|----------|-----------------|-----------------|-------|----------|
| E1-14    | GLRTHIDMVVMSATF | 257–271         |       |          |
| E1-17    | CASLYVGDLCGGVMYL | 272–286         | AVP1461| GSATLCSALYGDLCGSV |
| E1-18    | VGDLGCGLVMAAQVF | 277–291         | AVP1462| ALYVGDLCGSVLVQLQF |
| E1-27    | MTTNWSPTATMLAY  | 322–336         | AVP1469| MMNWSPTAAILVQQLRI |
| E1-28    | SPTATMLAYVMRVP  | 327–341         | AVP1469| MMNWSPTAAILVQQLRI |
| E2-31    | VGCPYYCFTPSPVVV | 504–518         |       |          |
| E2-42    | QGSWFGCTWMNSTGF | 548–562         |       |          |
| E2-43    | FGCTWMNSTFT GTKTC | 552–566      |       |          |
| E2-60    | WHYRCTNVMTF KIKR | 620–634        |       |          |
| E2-72    | PLLHSTTEWAILPCT | 668–682         |       |          |
| E2-78    | GLLHLHQINVQVYM | 692–706         |       |          |
| E2-79    | LHQNIVDVQIMYGLS | 696–710         |       |          |

Table 1. Anti-HCV peptides in our screen.
peptides did not interact with HCV receptors (SRB1, claudin-1, CD81 and occludin) (Fig. 6D), consistent with the lack of antiviral activity of these four peptides when incubated with the cells before infection.

**Discussion**

This study describes a novel strategy to screen HCV inhibitors. We synthesized 126 peptides covering the HCV genotype 2a strain JFH-1 envelope glycoprotein E1E2. Each peptide consisted of 15 amino acids (AA) composed of two adjacent overlapping 10-AA (for E1) or 11-AA (for E2) regions. By screening the inhibition of HCVcc infection, we identified four novel anti-HCV peptides located in E2 (E2-42, E2-43, E2-78, E2-79). However, the screening might miss some inhibitory peptides because those peptides are not totally overlapped. These novel peptides strongly inhibited HCV independent of genotype. Interestingly, E2-42 associated with E1 and E2. Our results indicated that these four peptides inhibit HCV entry at the post-attachment step and block cell-to-cell transmission. Peptide E2-42 binding to E1 or E2 may also inhibit the late steps of HCV life cycle, such as HCV package and release. These inhibitory peptides might be used to treat HCV in combination with other anti-HCV agents.

Viral entry is the first step of the HCV life cycle. Our study demonstrated that the four peptides inhibit HCVcc entry at the post-attachment step in a pan-genotypic manner. E2-42, E2-43, E2-78, and E2-79 exhibited broad-spectrum inhibitory effects against different genotypes of HCVcc, including gene type 2a: Jc1p7NS2Gluc2a
and J6CGluc2a; genotype 1a/2a: H77/JFHGluc2a; and genotype 1a/2a: HB/JFHGluc2a. The inhibition rate of these peptides for genotype 2a, genotype 1a/2a, genotype 1b/2a chimeric virus infection was 80%, 75% to 80%, and 60% to 70%, respectively. The inhibitory effects of peptides E2-42 and E2-43 were slightly greater than those of peptides E2-78 and E2-79.

In this study, we attempted to investigate the inhibitory mechanisms of E42/E42/E78/E79 on HCV. These peptides did not associate with HCV receptors, including CD81, SRB1, claudin 1, and occludin. Our data demonstrate that E42/E42/E78/E79 have no effects on HCV viral RNA replication. We speculate that E42 may block viral entry and spread via E1 and E2. Further studies are needed to understand the inhibitory mechanisms of E42/E42/E78/E79.

The design of synthetic peptides for inhibition of viral infection is a classic strategy. For example, Enfuvirtide, a 36-AA peptide derived from the HIV virus envelope glycoprotein gp41 transmembrane region inhibits HIV-1 entry and has been used for clinical treatment of HIV-1-infected patients19. Several groups have identified HCV entry inhibitory peptides derived from E1E2 15, 20. Consistent with these findings, we observed that peptides from similar regions, such as E1-17, E1-18, E1-27, and E2-28, inhibit HCV entry, which suggests that our methods are feasible. During the preparation of our manuscript, a study reported that the region covering E2-78 and E2-79 plays a role in inhibiting HCV entry21. We narrowed down the inhibitory peptides in this area to 15 AA, shorter than the peptide in the previous study. Our screen identified E2-42 and E2-43 as two novel entry inhibitory peptides. We were able to identify E2-42 and E2-43 because we used 15-AA peptides, while the other group used longer peptides.

The four peptides exhibited significant combination inhibition of HCV infection in combination with IFN-α2b or anti-CD81 monoclonal antibody in a dose-dependent manner. In addition, the combination of inhibitory peptides and IFN-α2b or CD81 monoclonal antibody had a broad-spectrum inhibitory effect on HCV infection. In the future, we will optimize the structure and amino acid composition of the inhibitory peptides to improve their inhibition efficiency. We will also combine the peptides with DAAs to inhibit HCV infection and thus provide a reference for improving clinical HCV combination therapy strategies.

In conclusion, we identified and characterized four new E2-derived HCV inhibitors. These inhibitors blocked HCV entry and suppressed HCV spread in cell culture, suggesting that they are strong candidates for further antiviral drug development. Furthermore, we determined that one of these peptides (E2-42), interacts with E1/E2; this interaction might play a role in the inhibition of HCV infection, opening a window to explore potential mechanisms of HCV entry.

**Methods**

**Cells and viruses.** The cell line Huh7.5/CD81, a derivative of Huh7 highly permissive for HCV-RNA replication and infection, was cultured in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen, Carlsbad, CA, USA) with 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA, USA), nonessential amino acids (Invitrogen, Carlsbad, CA, USA), 100 g/mL streptomycin (Invitrogen, Carlsbad, CA, USA), 100 IU/mL penicillin (Invitrogen, Carlsbad, CA, USA), and 2 mmol/L L-glutamine (Invitrogen, Carlsbad, CA, USA). The HCV JFH1-Luc-NS3-5B replicon-containing cell line was provided by Dr. Shan Cen (Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing). pFLJclp7NS2Gluc2a was a gift from Dr. Charles Rice (Rockefeller University, NYC, NY, USA). pFL/HBF/JFHGluc2a, pFLH77/JFHGluc2a and pFLJ6/JFHGluc2 were previously constructed in our lab22.

**Antibodies.** The primary mouse antibodies included anti-HCV core (Thermo, Waltham, MA, USA), anti-HCV NS5A (ViroGen Co, Watertown, MA, USA), anti-SRB1 antibody (BD, Franklin Lakes, NJ, USA), and anti-FLAG antibody (Sigma-Aldrich, St. Louis, MO, USA). The primary rabbit antibody was anti-claudin-1.
antibody (Abcam, Cambridge, MA, USA). Secondary antibodies included HRP-conjugated ECL goat anti-rabbit IgG, HRP-conjugated ECL goat anti-mouse IgG (Amersham Biosciences, Piscataway, NJ, USA), and goat anti-mouse IgG conjugated with AlexaFluor 594 (Invitrogen, Carlsbad, CA, USA).

**Synthesis of peptides.** A total of 126 peptides derived from the HCV genotype 2a JFH1 strain (GenBank no. AB047639) protein E1E2 were synthesized, of which 37 peptides were from HCV E1 and 89 peptides were from E2. Each peptide contained 15 amino acids, with 10 (for E1) or 11 (E2) amino acids of overlap between adjacent peptides.

**Production of cell culture-grown HCV (HCVcc).** pFLJC1p7NS2Gluc2a, pFLHB/JFHGluc2a, pFLH77/JFHGluc2a and pFLJ6/JFHGluc2a were linearized, further purified with ethanol and sodium acetate, and used as templates for in vitro RNA synthesis using the RiboMAX™ Large Scale RNA Production System-T7. The synthesized HCV subgenomic RNA was treated with DNase I (Promega, Madison, WI, USA), followed by acid phenol extraction to remove any remaining template DNA. Then, 10µg of RNA was electroporated into 2 × 10⁵ Huh7.5/CD81 cells (270 V, 970 µF), and 48 h later, the cell culture supernatants were filtered through 0.1-µm filters (Millipore, Billerica, MA, USA) and collected.

**HCV infection assay.** Huh7.5/CD81 cells were seeded in 48-well plates at a density of 1 × 10⁵/well before infection. The next day, the cells were infected with MOI = 0.05 focus forming unit (FFU)/cell in triplicate. Luciferase activity or HCV core expression level was assayed 72 h later.
Cytotoxicity assay. Cell viability was determined using the MTT Cell Viability Assay Kit from R&D Systems (Minneapolis, MN, USA) following the manufacturer’s instructions. Briefly, aliquots of $1.5 \times 10^4$ Huh7.5/CD81 cells/well were cultured in 96-well plates with fresh medium or medium with increasing concentrations of peptides for 48 h. The absorbance at 490 nm was measured with a 96-well plate reader. Each experiment was repeated at least three times.

Luciferase reporter assays. Huh7.5.1/CD81 cells were infected with HCVcc for 1 h, and Gaussia luciferase activity was assayed 72 h later.

DNA constructs. The DNA sequences encoding four peptides from E2 (GST-E2-N-42, E2-N-43, E2-N-78, E2-N-79) fused to the carboxyl terminus of GST were inserted into the EcoRI and XhoI sites of the pGEX4T-1 vector. The PCR primers were as follows: 5’-AATTCAGGGTCATGGTGGCTGGCGACGGTGGATGAAACCTCCATGTGGTTTCTGAC-3’ (GST-E2-N-42 forward); 5’-TCGAGTCAAGAAACCACTGGAGTTCTCATCCACGTGCAACGCAACCATGAGGCCCTGG-3’ (GST-E2-N-42 reverse); 5’-AATTCCTCGGCTGCACTGGATGAAACCTCCATGTGGTTTCTGAC-3’ (GST-E2-N-42 forward).
Constructs encoding CD81 were inserted into the EcoRI and XbaI sites of pCMV14-3XFLAG. The PCR primers were as follows: 5′-CCCAAGCTTATGTCCGGATCCTGGCTCCGCG-3′ (forward) and 5′-GCTCTAGATGTTTTCTGTCTATCATAG-3′ (reverse). Constructs encoding occludin were inserted into the HindIII and XbaI sites of pCMV14-3XFLAG. The PCR primers were as follows: 5′-CCCAAGCTTATGTCATCCAGGCCTCTTG-3′ (forward) and 5′-GCTCTAGATGTTTTCTGTCTATCATAG-3′ (reverse).

Figure 6. E2-42 interacts with HCV envelope proteins. (A) GST pulldown revealed that E2-42 associated with E1. Cell lysates from 293 T cells expressing JFH1 E1-FLAG were incubated with purified GST-N-E2-42, GST-N-E2-43, GST-N-E2-78, GST-N-E2-79, GST-C-E2-42, GST-C-E2-43, GST-C-E2-78, GST-C-E2-79 or GST, and the proteins were pulled down with glutathione-Sepharose beads. Bound proteins were detected by immunoblotting using anti-FLAG antibody. (B) GST pulldown identified an association between E2-42 and E2. Cell lysates from 293 T cells expressing JFH1 E2-FLAG were incubated with purified GST-N-E2-42, GST-N-E2-43, GST-N-E2-78, GST-N-E2-79, GST-C-E2-42, GST-C-E2-43, GST-C-E2-78, GST-C-E2-79 or GST, and the proteins were pulled down with glutathione-Sepharose beads. Bound proteins were detected by immunoblotting using anti-FLAG antibody. (C) Residues 548–551 of E2 is exposed in E2 structure. Ribbon representation of partial E2 model structure (PDB ID:4WHT) with residues 548–551 highlighted in yellow. (D) GST pulldown confirmed that E2-42 does not interact with HCV receptors. Cell lysates from Huh7.5.1 or 293 T cells expressing CD81-FLAG or occludin-FLAG were incubated with purified GST-N-E2-42, GST-N-E2-43, GST-N-E2-78, GST-N-E2-79, GST-C-E2-42, GST-C-E2-43, GST-C-E2-78, GST-C-E2-79 or GST, and the proteins were pulled down with glutathione-Sepharose beads.

CACCAAGACTTTGGTAC-3′ (GST-E2-N-43 forward); 5′-TCGAGTCAA
CAAGTCTTGGTGAAACCAGTGGAGTTCATCCACGTGCAGCCGAAG-3′ (GST-E2-N-43 reverse); 5′-AATTCGGTCTTCTCCACCTTCACCAGAACATCGTGGACGTACAATACATGTGAC-3′ (GST-E2-N-78 forward); 5′-TCGAGTCACATGTATTGTACGTCCACGATGTTCTGGTGAAGGTGGAGAAGACCG-3′ (GST-E2-N-78 reverse); 5′-AATTCCTTCACCAAGAACATCGTGGACGTACAATACATGTGACTCCACTGAGCTAC-3′ (GST-E2-N-79 forward); 5′-TCGAGTCATGAGAGGCCATACATGTATTGTACGTCCACGATGTTCTGGTGAAGCTC-3′ (GST-E2-N-79 reverse). The DNA sequences encoding four peptides from E2 (E2-C-42, E2-C-43, E2-C-78, E2-C-79) fused to the amino terminus of GST were inserted into the NcoI and SacI sites of pETGEX-CT. The PCR primers were as follows: 5′-GATGGAGCAGGGCTCATGGTTCGGCTGCACGTGGATGAACTCCACTGGTTTCGAGCT-3′ (GST-E2-C-42 forward); 5′-CGAAAACAGTGGATTTCATCCAGTGCCAGAGCACCAGTGGATGAACTCCACTGGTTTCGAGCT-3′ (GST-E2-C-42 reverse); 5′-GATGGAGGGTCTTCTCCACCTTCACCAGAACATCGTGGACTC-3′ (GST-E2-C-43 forward); 5′-GATGGAGGTGTCTTCTCCACCTTCACCAGAACATCGTGGACTC-3′ (GST-E2-C-43 reverse); 5′-GATGGAGGGTCTTCTCCACCTTCACCAGAACATCGTGGACTC-3′ (GST-E2-C-78 forward); 5′-CCATGTATTGTACGTCCACGATGTTCTGGTGAAGCTC-3′ (GST-E2-C-78 reverse); 5′-GATGGAGGTCCTACCAGAACATCTGGACGTAC-3′ (GST-E2-C-79 forward); 5′-GATGGAGGTCCTACCAGAACATCTGGACGTAC-3′ (GST-E2-C-79 reverse). The DNA sequences encoding four peptides from E2 (E2-C-42, E2-C-43, E2-C-78, E2-C-79) fused to the amino terminus of GST were inserted into the NcoI and SacI sites of pETGEX-CT. The PCR primers were as follows: 5′-CCCAAGCTTATGTCCGGATCCTGGCTCCGCG-3′ (forward) and 5′-GCTCTAGATGTTTTCTGTCTATCATAG-3′ (reverse). Constructs encoding CD81 were inserted into the EcoRI and XbaI sites of pCMV14-3XFLAG. The PCR primers were as follows: 5′-CCCAAGCTTATGTCCGGATCCTGGCTCCGCG-3′ (forward) and 5′-GCTCTAGATGTTTTCTGTCTATCATAG-3′ (reverse). Constructs encoding occludin were inserted into the HindIII and XbaI sites of pCMV14-3XFLAG. The PCR primers were as follows: 5′-CCCAAGCTTATGTCCGGATCCTGGCTCCGCG-3′ (forward) and 5′-GCTCTAGATGTTTTCTGTCTATCATAG-3′ (reverse).
GST pulldown. Expression of GST protein or the GST-peptide fusion protein was induced by 0.5 mM IPTG in E. coli Rosetta (DE3) at 37 °C for 4 h. The cells were then lysed with lysis buffer (50 mM Tris pH 6.8, 1 mM EDTA, 100 mM NaCl), and GST or GST-fused proteins were purified using glutathione-Sepharose beads. For the pulldown assay, the cell lysates were incubated with GST or GST-fused antibodies. After incubation at 4 °C for 1.5 h, the glutathione beads were pelleted and washed three times with PBS buffer. The protein samples were then boiled in SDS-containing loading buffer for gel electrophoresis followed by western blotting.

qRT-PCR analysis. HCV RNA was quantitated by qRT-PCR analysis. Briefly, RNA was isolated from the cell culture medium using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer’s protocol. qRT-PCR was performed on a C1000 thermal cycler (Bio-Rad, Hercules, CA, USA) with an artus HCV RG RT-PCR Kit (Qiagen, Germany). Each experiment was repeated at least three times.

Western blot analysis. HuH7.5/CD81 cells were lysed in ice-cold RIPA buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, and 0.5% sodium deoxycholate) supplemented with a protease inhibitor mixture (Sigma, St. Louis, MO, USA). The cell lysates were incubated on ice for 30 min, centrifuged, and resolved by 10% SDS-PAGE. The proteins were then transferred to a PVDF membrane (Pall, Port Washington, NY, USA), followed by blocking with 5% skim milk for 1 h and incubation with the selected primary antibody overnight at 4 °C. The following day, the membranes were incubated with the corresponding IRDye 800-labeled IgG secondary antibodies (Li-Cor Inc., Lincoln, NE, USA) and scanned using the Odyssey Infrared Imaging System (Li-Cor Inc., Lincoln, NE, USA).

Immunofluorescence Microscopy. HCV cell-to-cell transmission assay was performed according the reference26 and measured by immunofluorescence microscopy. Cells infected with HCV were washed with PBS, fixed with 4% paraformaldehyde, and permeabilized with 0.2% Triton X-100. The fixed cells were blocked with 1% bovine serum albumin and 1% normal goat serum in PBS. HCV NS5A protein in cells was detected by incubation with mouse anti-NS5A monoclonal antibody (ViroGen, Watertown, MA, catalogue No. 256-A) and visualized with secondary goat anti-mouse IgG conjugated to AlexaFluor 594 dye (Invitrogen, Carlsbad, CA, USA). The cover slips were mounted on slides with 4′,6-diamidino-2-phenylindole (DAPI) (Invitrogen, Carlsbad, CA, USA), and the HCV proteins were visualized by fluorescence microscopy (Olympus, Japan).

Statistical Analysis. The qRT-PCR, western blot and luciferase activity assays were performed in triplicate. The data were analyzed using a two-tailed paired Student’s t-test.

References
1. Gower, E., Estes, C., Blach, S., Razavi-Shearer, K. & Razavi, H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61, 545–57 (2014).
2. Gogela, N. A., Lin, M. V., Wisocky, J. L. & Chung, R. T. Enhancing our understanding of current therapies for hepatitis C virus (HCV). Curr HIV/AIDS Rep 12, 68–78 (2015).
3. Majumdar, A., Kitson, M. T. & Roberts, S. K. Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. Aliment Pharmacol Ther 43, 1276–1292 (2016).
4. Moradpour, D., Penin, F. & Rice, C. M. Replication of hepatitis C virus. Nat Rev Microbiol 5, 453–463 (2007).
5. Scarselli, E. et al. The human scavenger receptor class B type 1 is a novel candidate receptor for the hepatitis C virus. EMBO J 21, 5017–5025 (2002).
6. Pileri, P. et al. Binding of hepatitis C virus to CD81. Science 282, 938–941 (1998).
7. Evans, M. J. et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446, 801–805 (2007).
8. Ploss, A. et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457, 882–886 (2009).
9. Luppinger, I. et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 17, 589–595 (2011).
10. Sainz, B. Jr. et al. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med 18, 281–285 (2012).
11. Martin, D. N. & Uprichard, S. L. Identification of transferrin receptor 1 as a hepatitis C virus entry factor. Proc Natl Acad Sci USA 110, 10777–10782 (2013).
12. Qian, X. J., Zhu, Y. Z., Zhao, P. & Qi, Z. T. Entry inhibitors: New advances in HCV treatment. Emerg Microbes Infect 5, e3 (2016).
13. Fofana, I., Jilg, N., Chung, R. T. & Baumert, T. F. Entry inhibitors and future treatment of hepatitis C. Antiviral Res 104, 136–142 (2014).
14. Ding, Q., von Schaejen, M. & Ploss, A. The impact of hepatitis C virus entry on viral tropism. Cell Host Microbe 16, 562–568 (2014).
15. Liu, X., Chen, N., Lin, S. & Liu, M. Synthesized peptide 710–725 from HCV subtype 1a E2 glycoprotein blocks HCV infection. Cell Host Microbe 16, 525–535 (2014).
16. Lin, Q. et al. HCV peptide (C5A), an amphipathic alpha-helical peptide of hepatitis virus C, is an activator of N-formyl peptide receptor in human phagocytes. J Immunol 186, 2087–2094 (2011).
17. Qureshi, A., Thakur, N., Tandon, H. & Kumar, M. AVPdb: a database of experimentally validated antiviral peptides targeting medically important viruses. Nucleic Acids Res 42, D1147–1153 (2014).
18. Faison, P. et al. Hepatitis C Virus Envelope Glycoprotein E1 Forms Trimmers at the Surface of the Virion. J Virol 89, 10333–10346 (2015).
19. Matthews, T. et al. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Discov 3, 215–225 (2004).
20. Lu, X. et al. Identification of peptides that bind hepatitis C virus envelope protein E2 and inhibit viral cellular entry from a phage-display peptide library. Int J Mol Med 33, 1132–1138 (2014).
21. Chi, X. et al. Identification of a Potent and Broad-Spectrum Hepatitis C Virus Fusion Inhibitory Peptide from the E2 Stem Domain. Sci Rep 6, 25224 (2016).
22. Lu, S. et al. Characterization of Serinal Passage of 1b/2a Chimera Hepatitis C Virus Cell Culture System Carrying Envelope E1E2 Coding Gene from Hebein Strain of China. Biot Du Xue Bao 31, 647–652 (2015).
23. Barretto, N., Sainz, B. Jr., Hussain, S. & Uprichard, S. L. Determining the involvement and therapeutic implications of host cellular factors in hepatitis C virus cell-to-cell spread. J Virol 88, 5050–5061 (2014).
Acknowledgements
This work was supported by grants from National Key Plan for Research and Development of China (2016YFD0500300), State Megaproject for Infectious Disease Research of China (2013ZX10004601), National Natural Science Foundation of China (81373229, 81471955), National 863 High-tech R&D Program of China (2007AA02Z455), CAMS Innovation Fund for Medical Sciences (CIFMS) (2016-I2M-3-020), the Fundamental Research Funds for the Central Universities (3332013118, 2016ZX310047), and Program for Changjiang Scholars and Innovative Research Team in University (IRT13007). We thank Dr. Charles Rice, Takaji Wakita, and Shan Cen for reagents.

Author Contributions
L.Z. and W.T. conceived and designed the experiments; P.Y., L.Z., Y.D., S.L. and Y.L. performed the experiments; L.Z., F.Y., P.Y. and W.T. analyzed data; L.Z., P.Y. and F.Y. wrote the paper; All authors reviewed the manuscript.

Additional Information
Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017